The global electrophoresis market size was estimated at USD 3.17 billion in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030. This growth is attributed to the increasing prevalence of chronic diseases such as CVD and cancer, increasing industry academia collaborations coupled with the rising need for personalized medicines and technological advancements are major factors driving the market. Furthermore, increasing funding for genomics and proteomics research and rising number of clinical laboratories are likely to drive the market over the forecast period.
The rising prevalence of cancer and infectious diseases is driving the need for early diagnosis. In February 2024, WHO estimated the global cancer burden to reach an estimated number of 35 million new cases by 2050, a 77 % rise to that of 20 million in 2022. This increasing prevalence is driving demand for advanced diagnostic and treatment technologies, including electrophoresis reagents and systems. Electrophoresis is a crucial technique used in cancer research, diagnosis, and monitoring, enabling the separation and analysis of proteins, nucleic acids, and other biomolecules. Lung cancer is the leading cause of cancer death worldwide, accounting for 1.8 million deaths 18.7% of total cancer deaths in 2022.
Collaborations between academic institutions and industry players are fostering innovation in electrophoretic techniques, particularly in the fields of genomics, proteomics, and personalized medicine. These partnerships are leveraging advanced electrophoresis technologies to identify biomarkers, study disease mechanisms at a molecular level, and develop targeted therapies tailored to individual genetic profiles. Moreover, the increasing integration of high-throughput electrophoresis systems in clinical diagnostics and pharmaceutical research is accelerating the development of more precise and efficient analytical methods. In May 2022, a recent study published in the PLOS ONE Journal highlighted the use of gel electrophoresis to identify key proteins associated with tumor progression and molecular specificity in lung cancer subtypes. This technique allowed researchers to distinguish proteins from tumor cells, which can aid in accurate diagnosis and potentially contribute to the development of targeted therapies for specific lung cancer segments.
Technological advancements in electrophoresis kits and reagents have been transformative, enhancing the efficiency, accuracy, and versatility of electrophoretic techniques across various scientific and clinical applications. One key development lies in the formulation of novel gel matrices for gel electrophoresis, which offer improved resolution and faster separation of biomolecules such as DNA, RNA, and proteins. For instance, in September 2022, miniPCR bio, a leading provider of scientific equipment for researchers, introduced the BanditTM STEM Electrophoresis Kit, an innovative educational tool that enables students to construct and operate a fully functional gel electrophoresis device at an affordable price. This kit is designed to promote hands-on learning in the field of STEM education.
The market is further characterized by the integration of automated systems and robotics in electrophoresis platforms which has streamlined laboratory workflows. Automated electrophoresis instruments leverage microfluidic chip-based technology to seamlessly incorporate fluorescence detection, electrophoretic separation, and data analysis of biomolecules like proteins and nucleic acids into a single platform. For instance, the Experion analysis chip employs LabChip technology developed by Caliper Life Sciences, Inc. This microfluidic chip serves as a powerful, miniaturized laboratory, encapsulating the capabilities of multiple larger benchtop analytical instruments. Each chip features a network of microchannels that link the sample wells to a separation channel and buffer wells.
Furthermore, automated gel loading, sample handling, and data analysis processes minimize human error and improve reproducibility, making electrophoresis more accessible and reliable for researchers and clinicians. In addition, advancements in single-cell proteomics and plasma biomarker discovery are also boosting the need for electrophoresis technologies with higher throughput and reproducibility. Automation and miniaturization of electrophoresis workflows are key focus areas to meet these evolving research requirements.
Governments' initiatives, increasing funding, and substantial investments in genomics and proteomics are also driving the market growth. Major initiatives like the Yale Center for Genomics and Proteomics and the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium are providing significant funding to advance genomics and proteomics research. This is driving demand for high-performance electrophoresis reagents and systems to support these efforts. Furthermore, in October 2023, the Government of Canada announced an investment of USD 15 million over 5 years to create the Pan-Canadian Genome Library, the country's first national, centralized genomic data management system. The Library will allow for more personalized treatment of diseases, especially rare diseases. Such initiatives aimed at research building capabilities are poised to drive demand for electrophoresis systems and reagents.
This product will be delivered within 1-3 business days.
The rising prevalence of cancer and infectious diseases is driving the need for early diagnosis. In February 2024, WHO estimated the global cancer burden to reach an estimated number of 35 million new cases by 2050, a 77 % rise to that of 20 million in 2022. This increasing prevalence is driving demand for advanced diagnostic and treatment technologies, including electrophoresis reagents and systems. Electrophoresis is a crucial technique used in cancer research, diagnosis, and monitoring, enabling the separation and analysis of proteins, nucleic acids, and other biomolecules. Lung cancer is the leading cause of cancer death worldwide, accounting for 1.8 million deaths 18.7% of total cancer deaths in 2022.
Collaborations between academic institutions and industry players are fostering innovation in electrophoretic techniques, particularly in the fields of genomics, proteomics, and personalized medicine. These partnerships are leveraging advanced electrophoresis technologies to identify biomarkers, study disease mechanisms at a molecular level, and develop targeted therapies tailored to individual genetic profiles. Moreover, the increasing integration of high-throughput electrophoresis systems in clinical diagnostics and pharmaceutical research is accelerating the development of more precise and efficient analytical methods. In May 2022, a recent study published in the PLOS ONE Journal highlighted the use of gel electrophoresis to identify key proteins associated with tumor progression and molecular specificity in lung cancer subtypes. This technique allowed researchers to distinguish proteins from tumor cells, which can aid in accurate diagnosis and potentially contribute to the development of targeted therapies for specific lung cancer segments.
Technological advancements in electrophoresis kits and reagents have been transformative, enhancing the efficiency, accuracy, and versatility of electrophoretic techniques across various scientific and clinical applications. One key development lies in the formulation of novel gel matrices for gel electrophoresis, which offer improved resolution and faster separation of biomolecules such as DNA, RNA, and proteins. For instance, in September 2022, miniPCR bio, a leading provider of scientific equipment for researchers, introduced the BanditTM STEM Electrophoresis Kit, an innovative educational tool that enables students to construct and operate a fully functional gel electrophoresis device at an affordable price. This kit is designed to promote hands-on learning in the field of STEM education.
The market is further characterized by the integration of automated systems and robotics in electrophoresis platforms which has streamlined laboratory workflows. Automated electrophoresis instruments leverage microfluidic chip-based technology to seamlessly incorporate fluorescence detection, electrophoretic separation, and data analysis of biomolecules like proteins and nucleic acids into a single platform. For instance, the Experion analysis chip employs LabChip technology developed by Caliper Life Sciences, Inc. This microfluidic chip serves as a powerful, miniaturized laboratory, encapsulating the capabilities of multiple larger benchtop analytical instruments. Each chip features a network of microchannels that link the sample wells to a separation channel and buffer wells.
Furthermore, automated gel loading, sample handling, and data analysis processes minimize human error and improve reproducibility, making electrophoresis more accessible and reliable for researchers and clinicians. In addition, advancements in single-cell proteomics and plasma biomarker discovery are also boosting the need for electrophoresis technologies with higher throughput and reproducibility. Automation and miniaturization of electrophoresis workflows are key focus areas to meet these evolving research requirements.
Governments' initiatives, increasing funding, and substantial investments in genomics and proteomics are also driving the market growth. Major initiatives like the Yale Center for Genomics and Proteomics and the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium are providing significant funding to advance genomics and proteomics research. This is driving demand for high-performance electrophoresis reagents and systems to support these efforts. Furthermore, in October 2023, the Government of Canada announced an investment of USD 15 million over 5 years to create the Pan-Canadian Genome Library, the country's first national, centralized genomic data management system. The Library will allow for more personalized treatment of diseases, especially rare diseases. Such initiatives aimed at research building capabilities are poised to drive demand for electrophoresis systems and reagents.
Global Electrophoresis Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the publisher has segmented the global electrophoresis market report based on product, application, end use, and region:- Electrophoresis Product Outlook (Revenue, USD Million, 2018 - 2030)
- Electrophoresis Reagents
- Protein Electrophoresis Reagents
- Nucleic Acid Electrophoresis Reagents
- Electrophoresis Systems
- Gel Electrophoresis Systems
- Capillary Electrophoresis Systems
- Gel Documentation Systems
- Software
- Electrophoresis Application Outlook (Revenue, USD Million, 2018 - 2030)
- Research Applications
- Diagnostics Applications
- Quality Control and Process Validation
- Electrophoresis End use Outlook (Revenue, USD Million, 2018 - 2030)
- Academic and Research Institutes
- Pharmaceutical & Biotechnology Companies
- Hospital & Diagnostic Centers
- Other End use
- Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- Saudi Arabia
- South Africa
- UAE
- Kuwait
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Electrophoresis Market Variables, Trends & Scope
Chapter 4. Electrophoresis Market: Product Estimates & Trend Analysis
Chapter 5. Electrophoresis Market: Application Estimates & Trend Analysis
Chapter 6. Electrophoresis Market: End Use Estimates & Trend Analysis
Chapter 7. Electrophoresis Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- Merck KGaA
- GE Healthcare
- QIAGEN N.V.
- Lonza Group Ltd.
- Agilent Technologies, Inc.
- PerkinElmer, Inc.
- Danaher Corporation
- Harvard Bioscience, Inc.
- Shimadzu Corporation
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | July 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 3176.46 Million |
| Forecasted Market Value ( USD | $ 4489.86 Million |
| Compound Annual Growth Rate | 5.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
